DAWN, DMARDS AND SHARED CARE
Reducing the risk of harm to patients associated with disease-modifying anti-rheumatic drugs (DMARDs) Phillipa Daniels-Holgate BPharm (Hons), MPhil, PhD, MRPharmS, Pharmacist Specialist – Project Development, KGH NHSFT Introduction Disease-modifying anti-rheumatic drugs (DMARDs, conventional and biologic) provide the cornerstone of treatment for chronic inflammatory diseases, but these medicines are potentially toxic. Patients receiving DMARDs are at […]